Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-CORT125281 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Study Participants | EXPERIMENTAL | On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast. |
| Name | Type | Description |
|---|---|---|
| 14C-CORT125281 | DRUG | 14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C |
Inclusion Criteria: * Body mass index 18.0 to 30.0 kg/m\^2, inclusive * Provide written informed consent * Have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day) * Able to swallow capsules * Adhere to specified contraception requirements. Exclusion Criteria: * H...
14C-CORT125281 is a small molecule drug candidate developed by Corcept Therapeutics Incorporated. It has been studied in a Phase 1 clinical trial in healthy male participants. The compound is a carbon-14 labeled version of CORT125281, used to study how the drug is absorbed, metabolized, and excreted in the body.
14C-CORT125281 is being developed by Corcept Therapeutics Incorporated, which trades on the Nasdaq under the ticker CORT. The company sponsored the Phase 1 trial of the compound. Corcept is a biopharmaceutical company focused on the development of drugs that modulate the cortisol receptor pathway.
14C-CORT125281 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug has not been approved by the FDA and remains investigational. Phase 1 trials typically assess safety, tolerability, and pharmacokinetics in a small number of participants.
14C-CORT125281 has been studied in one completed Phase 1 trial, NCT03877952, titled Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants. The trial enrolled 6 healthy male participants in the United Kingdom. It was an uncontrolled, non-randomized study designed to characterize the drug's metabolism and excretion.
14C-CORT125281 is a carbon-14 radiolabeled form of CORT125281. The radiolabel allows researchers to track the drug's absorption, distribution, metabolism, and excretion in the body. The Phase 1 trial NCT03877952 specifically used this labeled version to study mass balance recovery and the metabolite profile of CORT125281.